Agreement – June 12, 2025
Key2Brain enters worldwide licensing agreement with Chiesi Group
The two companies will advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system.